- Identify and validate new market opportunities across oncology, clinical, research, and applied genomics
- Develop market development strategies with clear priorities and measurable commercial outcomes
- Build partnerships with customers, KOLs, academic institutions, clinical organizations, biopharma companies, and professional societies
- Lead evidence-generation initiatives that support adoption and market entry
- Translate scientific and market insights into compelling commercial value propositions
- Support sales teams on strategic accounts, pipeline development, and complex opportunities
- Provide input into product, workflow, and portfolio strategy
- Help shape standards, guidelines, and market-access pathways where appropriate
- Build repeatable frameworks and best practices as the global Market Development function grows
- An advanced degree in genomics, molecular biology, life sciences, medicine, or a related discipline is preferred. A PhD, MD, or MBA is advantageous.
- Significant experience to Next Generation Sequencing or extensive experience in genomics or oncology.
- Demonstrated success in market development, commercialization, strategic partnerships, or market creation
- Strong understanding of clinical, research, and applied genomics markets across the Americas
- Experience working with KOLs, scientific collaborators, professional societies, or policy stakeholders
- Ability to translate complex science into clear commercial and customer value
- Strong cross-functional leadership and influence in a global, matrixed organization
- A hands-on, entrepreneurial approach and comfort working in an evolving environment
- An established network across relevant oncology, genomics, clinical, biopharma, or policy communities
- Willingness to 30% travel across the Americas
Oxford Nanopore Technologies: Our goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology for faster, information rich, accessible and affordable molecular analysis. The first application is DNA/RNA sequencing, and the technology is in development for the analysis of other types of molecules including proteins. The technology is used to understand and characterise the biology of humans and diseases such as cancer, plants, animals, bacteria, viruses, and whole environments. With a thriving culture of ambition and strong innovation goals, Oxford Nanopore is a UK headquartered company with global operations and customers in more than 125 countries.
Skills Required
- Experience with Next Generation Sequencing or extensive genomics/oncology experience
- Demonstrated success in market development, commercialization, strategic partnerships, or market creation
- Strong understanding of clinical, research, and applied genomics markets across the Americas
- Experience working with KOLs, scientific collaborators, professional societies, or policy stakeholders
- Ability to translate complex science into clear commercial and customer value
- Strong cross-functional leadership and influence in a global, matrixed organization
- Hands-on, entrepreneurial approach and comfort working in an evolving environment
- Established network across oncology, genomics, clinical, biopharma, or policy communities
- Willingness to travel up to 30% across the Americas
- Advanced degree in genomics, molecular biology, life sciences, medicine, or related discipline (PhD, MD, or MBA advantageous)
Oxford Nanopore Technologies Compensation & Benefits Highlights
The following summarizes recurring compensation and benefits themes identified from responses generated by popular LLMs to common candidate questions about Oxford Nanopore Technologies and has not been reviewed or approved by Oxford Nanopore Technologies.
-
Fair & Transparent Compensation — Pay is considered good to above average across many roles, with employer-provided ranges visible for several U.S. commercial and applications positions and company materials emphasizing market‑competitive base pay. Commercial and some senior technical posts, particularly in the U.S., are positioned as competitive and often paired with strong variable components.
-
Equity Value & Accessibility — All‑employee share plans in the UK and a U.S. employee stock purchase plan indicate broad access to equity as part of total reward. Company communications highlight attractive bonus and share plans that add meaningful upside beyond base pay.
-
Healthcare Strength — U.S. roles indicate strong health insurance and core protections, while official materials and country overviews reference private medical coverage and wellbeing support. These elements position the health package as a notable strength alongside cash compensation.
Oxford Nanopore Technologies Insights
What We Do
Our goal is to enable the analysis of anything, anywhere, by anyone. We have developed the world’s first and only nanopore DNA and RNA sequencing platform. It’s a new generation of sequencing technology — the only one to offer: scalability to portable or ultra-high throughput formats, real-time data delivery, and the ability to elucidate rich biological data. We are aiming to disrupt the way that biological analyses are currently performed, and open up new applications that have a profound, positive impact on society. Our devices offer real-time analysis, for rapid insights, in fully scalable formats — from pocket to population scale — and the technology is being used in more than 100 countries worldwide. Founded in 2005 as a spin-out from the University of Oxford, the company now employs more than 600 people from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialisation. The management team, led by CEO Dr Gordon Sanghera, has a track record of delivering disruptive technologies to the market.
